Aggregate out-of-pocket costs $427,069.74 for those undergoing LCS and downstream procedure; OOP cost per episode was $62.46

Researchers say minimization of false positives necessary prior to clinical use

Mesothelioma incident cases and deaths associated with mesothelioma decreased after 20 years of complete ban on asbestos

National LCS rates were unchanged between 2019 and 2020; significant declines seen in five states and increases recorded in 19 states

Seven graded recommendations and nine ungraded consensus statements developed for lung cancer screening

Risks for all-cause mortality, cancer-specific mortality, disease progression reduced for those quitting after diagnosis

No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease